{"commentary":{"count":37,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":18,"podcast":10,"youtube":9},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04770896\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"IMbrave251","nct_id":"NCT04770896","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=imbrave251-nct04770896. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"IMbrave251","arms":[{"description":"Participants will receive atezolizumab plus lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","label":"Atezolizumab + Lenvatinib or Sorafenib","type":"EXPERIMENTAL"},{"description":"Participants will receive lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","label":"Lenvatinib or Sorafenib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-10-14","type":"ESTIMATED"},"conditions":["Unresectable Hepatocellular Carcinoma"],"enrollment":{"count":557,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Atezolizumab","type":"DRUG"},{"name":"Lenvatinib","type":"DRUG"},{"name":"Sorafenib","type":"DRUG"}],"last_update":"2026-08-25","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-10-14","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Randomization until death from any cause (approximately 42 months)"}],"references":[],"start_date":{"date":"2021-04-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab","url":"https://clinicaltrials.gov/study/NCT04770896"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/imbrave251-nct04770896"}